EUVIMEDEUVIMED entdecken
Open Access

TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer

Jibran Ahmed, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K Nesline, Sarabjot Pabla, Jeffrey M Conroy, Paul DePietro, Jason K Sicklick, Shumei Kato, Razelle Kurzrock

American Journal of Cancer Research · 2024 · 14 (5) · 2493-2506

DOI: 10.62347/mqff6404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Cancer Research, 2024. Verfasst von Jibran Ahmed und 10 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health Bethesda, MD, …. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TIM-3, an inhibitory checkpoint receptor, may invoke anti-PD-1/anti-PD-L1 immune checkpoint inhibitor (ICI) resistance. The predictive impact of TIM-3 RNA expression in various advanced solid tumors among patients treated with ICIs is yet to be determined, and their prognostic significance also remains unexplored. We investigated TIM-3 transcriptomic expression and clinical outcomes. We examined TIM-3 RNA expression data through the OmniSeq database. TIM-3 transcriptomic patterns were calibrated against a reference population (735 tumors), adjusted to internal housekeeping genes, and calculated as percentiles. Overall, 514 patients (31 cancer types; 489 patients with advanced/metastatic disease and clinical annotation) were assessed. Ninety tumors (17.5% of 514) had high (≥75th percentile RNA rank) TIM-3 expression. Pancreatic cancer had the greatest proportion of TIM-3 high expressors (36% of 55 patients). Still, there was variability within cancer types with, for instance, 12.7% of pancreatic cancers harboring low TIM-3 (

Schlagwörter

Stichwörter der Autor:innen

RNA expressionTIM-3immune-checkpoint inhibitorssolid tumors

Autor:innen und Institutionen

  • Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health Bethesda, MD, The United Sates.
  • Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center La Jolla, CA, The United States.
  • Dartmouth Cancer Center, Hematology and Medical Oncology Lebanon, NH, The United States.
  • OmniSeq Inc. (Labcorp) Buffalo, NY, The United States.
  • Department of Surgery, Division of Surgical Oncology, University of California San Diego San Diego, CA, The United States.
  • Department of Pharmacology, University of California San Diego San Diego, CA, The United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Ahmed, J., Nishizaki, D., Miyashita, H., Lee, S., Nesline, M. K., Pabla, S., Conroy, J. M., DePietro, P., Sicklick, J. K., Kato, S., & Kurzrock, R. (2024). TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer. American Journal of Cancer Research, 14(5), 2493-2506. https://doi.org/10.62347/mqff6404

Vancouver

Ahmed J, Nishizaki D, Miyashita H, Lee S, Nesline MK, Pabla S, et al. TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer. American Journal of Cancer Research. 2024;14(5):2493-2506. doi:10.62347/mqff6404

BibTeX
@article{Ahmed2024,
  author = {Ahmed, Jibran and Nishizaki, Daisuke and Miyashita, Hirotaka and Lee, Suzanna and Nesline, Mary K and Pabla, Sarabjot and Conroy, Jeffrey M and DePietro, Paul and Sicklick, Jason K and Kato, Shumei and Kurzrock, Razelle},
  title = {TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer},
  journal = {American Journal of Cancer Research},
  year = {2024},
  volume = {14},
  number = {5},
  pages = {2493--2506},
  doi = {10.62347/mqff6404}
}
Kostenlos starten →